Mostrar registro simples

dc.contributor.authorChakr, Rafael Mendonça da Silvapt_BR
dc.contributor.authorEspírito Santo, Rafaela Cavalheiro dopt_BR
dc.contributor.authorSantos, Leonardo Peterson dospt_BR
dc.contributor.authorSpannenberger, Kaleb Pintopt_BR
dc.contributor.authorSilva, Marielle Moro dapt_BR
dc.contributor.authorMoraes, Mateus Espindola dept_BR
dc.contributor.authorBueno, Juliapt_BR
dc.contributor.authorCardoso, Paula Schopronipt_BR
dc.contributor.authorGasparin, Andrese Alinept_BR
dc.contributor.authorHax, Vanessapt_BR
dc.date.accessioned2025-01-30T06:49:02Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn2357-9730pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/284181pt_BR
dc.description.abstractIntroduction: In knee osteoarthritis patients that benefit from chronic pain management and physical activity, the additional impact of duloxetine over and above exercise is yet to be determined. Our goal was to study the effects of duloxetine on muscle mass, strength, physical performance, pain, stiffness and physical function in sedentary patients with painful knee osteoarthritis treated with a home-based exercise (HE) program. Methods: Adults with painful knee osteoarthritis and lower physical performance were assigned to receive duloxetine (60mg/d) or placebo, in addition to HE therapy. The primary endpoint was the difference in short physical performance battery (SPPB) between groups at week 12. Secondary endpoints included 12-week changes in muscle mass by dual-energy X-ray absorptiometry (appendicular skeletal muscle mass index – ASMI), strength by handgrip (HG) and knee extension (KE) maximal isometric voluntary contraction, pain by visual analog scale (VAS) and pain, stiffness and physical function by Western Ontario McMaster Universities (WOMAC) questionnaire. Results: Twenty-four participants were included. After 12 weeks, HE+duloxetine showed no benefit in SPPB when compared to HE+placebo (p=0.456) and both groups significantly improved SPPB when compared to baseline [HE+duloxetine: 1.52 (95%CI 0.53 to 2.51); HE+placebo: 2.00 (95%CI 1.23 to 2.77)]. Both groups significantly improved WOMAC, with no differences between them (p=0.389). Only HE+duloxetine group improved pain VAS [-2.26cm (95%CI -4.08 to -0.44)], while only HE+placebo group improved ASMI [0.4Kg/m2 (95%CI 0.0 to 0.9)] and KE strength [11.8Kg (95%CI 4.3 to 19.2)]. HE+duloxetine group performed less minutes of exercise than HE+placebo group (310 vs. 692, p=0.015). Adverse events rates were similar between groups. Conclusions: Duloxetine did not additionally improve physical performance, pain, stiffness and physical function of patients with lower physical performance and painful KOA treated with exercise. Muscle mass and muscle strength gains were only observed in the placebo group perhaps due to greater exercise adherence, but larger studies are needed to address this hypothesis.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofClinical and biomedical research. Porto Alegre. Vol. 43, no. 4 (2023), p. 340-349pt_BR
dc.rightsOpen Accessen
dc.subjectOsteoarthritisen
dc.subjectOsteoartrite do joelhopt_BR
dc.subjectPainen
dc.subjectTerapia por exercíciopt_BR
dc.subjectSarcopeniaen
dc.subjectCloridrato de duloxetinapt_BR
dc.subjectMedição da dorpt_BR
dc.subjectMúsculo esqueléticopt_BR
dc.subjectProjetos pilotopt_BR
dc.titleShould duloxetine be added to exercise to treat sedentary patients with painful knee osteoarthritis? : A pilot studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001218066pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples